Is treatment of latent tuberculosis infection contraindicated in a 1‑year‑old child with acute lymphoblastic leukemia?

Treatment of Latent TB in a 1-Year-Old with ALL

Latent tuberculosis treatment is NOT contraindicated in a 1-year-old child with acute lymphoblastic leukemia; in fact, screening and treatment are strongly recommended because these patients face markedly elevated risk of TB reactivation due to intensive immunosuppressive chemotherapy. 1, 2

Why LTBI Treatment is Critical in Pediatric ALL

• Children with hematological malignancies have a 2–40 times higher relative risk of developing active TB disease compared to the general population due to profound immunosuppression from chemotherapy. 2

• Patients with acute leukemia are specifically identified as candidates for organ/hematopoietic stem-cell transplantation-level immunosuppression, which carries a strong recommendation for LTBI evaluation and treatment before or during therapy. 1

• Active TB during ALL treatment forces alteration or rescheduling of chemotherapy in up to 70% of cases, and this disruption is associated with significantly higher mortality. 3

• TB-related mortality in acute leukemia patients reaches 10%, making prevention through LTBI treatment a life-saving intervention. 3

Pre-Treatment Evaluation Required

Before starting LTBI therapy in your 1-year-old ALL patient, you must:

• Confirm LTBI using tuberculin skin test (TST) ≥10 mm induration or interferon-gamma release assay (IGRA); however, note that immunosuppressed children may have false-negative results, so combined TST-IGRA testing increases sensitivity. 1, 2

• Exclude active TB disease with chest radiograph before initiating LTBI therapy—this is non-negotiable because treating active TB as if it were latent infection leads to acquired drug resistance and treatment failure. 1

• Review chest imaging for findings consistent with prior TB infection (calcified granulomas, apical scarring), which are present in 30% of TST-positive leukemia patients and support the decision to treat. 4

Recommended LTBI Treatment Regimens for This Child

The CDC guidelines provide a hierarchy of regimens that apply to children of all ages:

Preferred Regimens (Highest Completion Rates)

• 3 months of weekly isoniazid plus rifapentine is the preferred regimen with strong evidence and moderate quality, offering excellent tolerability and higher completion rates than longer regimens. 5

• 4 months of daily rifampin is also preferred with strong evidence (moderate quality in HIV-negative patients), though data in children <15 years specifically support 2–3 months of isoniazid plus rifampin as equally effective. 5

• 3 months of daily isoniazid plus rifampin has conditional recommendation with low-quality evidence but appears as effective as 6-month isoniazid in children aged <15 years, with no difference in TB disease development or adverse effects requiring discontinuation. 5

Alternative Regimens

• 6 months of daily isoniazid is strongly recommended for HIV-negative children of all ages but has lower completion rates due to longer duration. 5

• 9 months of daily isoniazid is conditionally recommended for all ages but faces the same adherence challenges. 5, 6, 7

Safety and Tolerability in Acute Leukemia

• LTBI therapy is well tolerated in acute leukemia patients, with 81.6% of TST-positive leukemia patients completing intended therapy in a Canadian cancer center study. 4

• Hepatotoxicity from anti-TB therapy occurs in 35% of acute leukemia patients, but this is manageable and should not prevent treatment initiation. 3

• No patients who received LTBI therapy in the acute leukemia cohort developed active TB, demonstrating the protective efficacy of treatment. 4

• Drug-induced liver toxicity does not appear to be more severe in acute leukemia patients compared to the general population receiving LTBI therapy. 4

Critical Pitfalls to Avoid

• Do NOT delay LTBI therapy while waiting for "optimal" timing during chemotherapy—the risk of TB reactivation is present throughout treatment, and early prophylaxis prevents the need to alter or reschedule chemotherapy later. 1, 3

• Do NOT skip screening based on low local TB incidence—even in low-incidence countries like Italy, 11% of acute leukemia patients test positive for LTBI, and in Canada, 9.5% were TST-positive. 4, 8

• Do NOT assume a negative TST/IGRA rules out LTBI in an immunosuppressed child—consider combined testing or empiric treatment if epidemiologic risk factors are present (birth in TB-endemic country, household TB exposure). 2

• Do NOT use rifampin-containing regimens without first excluding active TB, as monotherapy-equivalent exposure can select for rifampin resistance if undiagnosed active disease is present. 1

Drug-Drug Interaction Considerations

• Rifamycins interact with many chemotherapy agents, but these interactions are manageable and should not be an absolute barrier to LTBI treatment—rifapentine has fewer interactions than rifampin. 5

• Isoniazid-based regimens have minimal drug interactions with ALL chemotherapy and may be preferred if rifamycin interactions are prohibitive. 5

Practical Implementation

For your 1-year-old ALL patient, the optimal approach is:

1. Screen with TST (and IGRA if available) before or immediately after starting induction chemotherapy. 1, 4

2. Obtain chest radiograph to exclude active TB. 1

3. If TST/IGRA positive and active TB excluded, start 3 months of weekly isoniazid plus rifapentine (preferred for adherence) or 3 months of daily isoniazid plus rifampin (well-studied in children <15 years). 5

4. Monitor liver function monthly during LTBI therapy, as hepatotoxicity is the main adverse effect. 4, 3

5. Continue ALL chemotherapy without delay—LTBI treatment and chemotherapy can be administered concurrently. 4, 3